No Detail Found!

Synthesis and α-glucosidase inhibition studies of norfloxacin- acetanilide hybrids

Author(s)
Kamran Walayat Department of Chemistry, Government College University,Faisalabad,Pakistan
Matloob Ahmad Department of Chemistry, Government College University,Faisalabad,Pakistan
Usman Ali Ashfaq Department of Bioinformatics and Biotechnology, Government College University,Faisalabad,Pakistan
Zulfiqar Ali Khan Department of Chemistry, Government College University,Faisalabad,Pakistan
Sadia Sultan Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia; Atta-ur-Rahman Institute for Natural Products Discovery (AuRIns), Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia
Abstract
a-Glucosidase inhibitors occupy a prominent position among the various treatments of type-2 diabetes mellitus (DM2). In this study, a series of new norfloxacin-acetanilide hybrid molecules were synthesized and screened for a-glucosidase inhibition activity. The synthetic methodology involves the synthesis of a series of a-bromoacetanilides by condensing bromoacetyl bromide with various substituted anilines. These a-bromoacetanilides were coupled with norfloxacin in DMF to get the titled hybrids. The structure elucidation of synthesized compounds were characterized by 1H NMR, 13C NMR and LC-MS. Finally, the compounds were screened for their a-glucosidase inhibition activity using acarbose as a reference drug (IC50 =58 µM). Among the tested compounds, 3i and 3j displayed potent a-glucosidase inhibition activity with IC50 values of 7.81±0.038 and 5.55±0.012 µM respectively. In-addition, 3m, 3f and 3k were demonstrated moderate alpha-glucosidase inhibition activities with IC50 values of 52.905±0.041, 23.79± 0.087 and 23.06±0.026 µM respectively. The structure-activity relationship was established with the help of molecular docking by using Molecular Operating Environment software (MOE 2014).
Publication Details
Page(s) 1909-1915
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP5, Year: 2021

Request the full text from PASTIC

Keywords
a-glucosidase inhibition activity, Norfloxacin derivatives, molecular docking, anti-diabetic studies
References
Adhikary KK,Lee HW .2011 .Nucleophilic substitution reactions of N-methyl α-Bromoacetanilides with benzylamines in dimethyl sulfoxide. Bull. Korean Chem. Soc., 32(3) : 857-862.
Akhtar R,Zahoor AF,Rasul A,Khan SG,Ali KG .2021 .In-vitro cytotoxic evaluation of newly designed ciprofloxacinoxadiazole hybrids against human liver tumor cell line (Huh7). Pak. J. Pharm. Sci., 34(3) : 1143-1148.
Berhe A,Russom M,Bahran F,Hagos G F .2019 .Ciprofloxacin and risk of hypolycemia in non-diabetic patients. J. Med. Case Rep, 13(1) : 142.
Cho NH,Shaw JE,Karuranga S,Huang Y,da Rocha Fernandes JD,Ohlrogge AW,Malanda B .2018 .IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract, 138 : 271-281.
Dash RP,Babu RJ,Srinivas NR .2018 .Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica., 48(1) : 89-108.
El Ghandour S and Azar ST .2015 .Dysglycemia associated with quinolones. Prim. Care Diabetes, 9(3) : 168-171.
Gharib HM,Abajy MY,Omaren A .2020 .Investigating the effect of some fluoroquinolones on blood glucose and insulin levels in STZ-induced diabetic wistar rats. Res. J. Pharm. Technol., 13(12) : 5993-5998.
Granados J,Ceballos M,Amariles P .2018 .Hypo or hyperglycemia associated with fluoroquinolone use. Rev. Med, 146(5) : 618-626.
Jimenez-Montero JG .2007 .Am Diabetes Assoc2019. , : 2017.
Kulkarni S,Agarwal DK,Pallavi A .2017 .Development of a novel method for the analysis of the drug in low concentration using an antidiabetic drug 'Voglibose' for the study. J. Pharm. Res. Int., 19(2) : 1-9.
Mohammadi-Khanaposhtani M,Rezaei S,Khalifeh R,Imanparast S,Faramarzi MA,Bahadorikhalili S,Safavi M,Bandarian F,Esfahani EN,Mahdavi M,Larijani B M .2018 .- glucosidase inhibition and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes. Bioorg. Chem, 80 : 288-295.
Okpana FO,Akah PA .2018 .. Effect of Diabetes on the Pharmacokinetic Profile of Fluoroquinolones. Int. J. Med, 6(2) : 21-27.
Oniga SD,Palage MD,Araniciu C,Marc G,Oniga O,Vlase L,Prisacari V,Valica V,Curlat S,Uncu L S .2018 .Design, synthesis, molecular docking and antibacterial activity evaluation of some novel norfloxacin analogues. Farmacia, 66(6) : 1048-1058.
Qian D,Zhang T,Zheng P,Liang Z,Wang S,Xie J,Zhao L,Zhang Y,Situ B Y .2018 .Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Ther., 9, (5) : 1945-1958.
Saad NA,Elberry AA,Samy Matar H,Hussein RR H .2021 .Effect of ciprofloxacin vs levofloxacin on QTc  interval and dysglycemia in diabetic and non  diabetic patients. Int. J. Clin. Pract, 75(5) : e14072.
Sabo A,Tomas A,Tomic N,Mikov M,Horvat O,Popovic R .2015 .Pharmacokinetic/ pharmacodynamic based dosing of ciprofloxacin in complicated urinary tract infections. Bangladesh J. Pharmacol., 10(3) : 621-626.
Saddique FA,Ahmad M,Ashfaq UA,Ahmad MN,Anjum MN,Mohsin NUA,Aslam S NUA .2019 .Alphaglucosidase inhibition and molecular docking studies of 1, 2-benzothiazine 1, 1-dioxide based carbohydrazides. Pak. J. Pharm. Sci., 32(6 Supp)) : 2829-2834.
Sohretoglu D,Sari S,Ozel A,Barut B .2017 .α- Glucosidase inhibitory effect of Potentilla astracanica and some isoflavones: Inhibition kinetics and mechanistic insights through in vitro and in silico studies. Int. J. Biol. Macromol, 105 : 1062-1070.
Sriram D,Yogeeswari P,Senchani G,Banerjee D G .2007 .Newer tetracycline derivatives: Synthesis, antiHIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg. Med, 17(8) : 2372-2375.
Suresh N,Nagesh HN,Renuka J,Rajput V,Sharma R,Khan IA,Gowri CSKV,- CSKV,- CSKV .2014 .-(4-(2-(4-substitutedpiperazin-1-yl) acetyl) piperazin-1-yl) quinoline-3-carboxylic acid derivatives as anti-tubercular and antibacterial agents. Eur. J. Med, 71 : 324-332.
Taj S,Ashfaq UA,Aslam S,Ahmad M,Bhatti SH .2019 .Alpha-glucosidase activity of novel pyrazolobenzothiazine 5, 5-dioxide derivatives for the treatment of diabetes mellitus. In vitro combined with molecular docking approach. , 74(11) : 1523-1530.
Teyhoo M,Hosseini F,Ardestani MS,Ghorbani M .2020 .Synthesis and evaluation of a novel nanosized anionic linear globular dendrimer G2-ciprofloxacin conjugate against prostate cancer. Pak. J. Pharm. Sci., 33(6) : 2589-2594.
Walayat K,Ahmad M,Rasul A,Aslam S,Anjum MN,Sultan S,Iqbal M .2020 .Synthesis, characterization and antimicrobial activity of norfloxacin based acetohydrazides. Pak. J. Pharm. Sci., 33(2) : 855-860.
Yadav V,Talwar P .2019 .Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed, 111 : 934-946.
Zhang B,Watt JM,Cordiglieri C,Dammermann W,Mahon MF,Flügel A,Guse AH,Potter BV .2018 .Small molecule antagonists of NAADP-induced Ca 2+ release in T-Lymphocytes suggest potential therapeutic agents for autoimmune disease. Sci. Rep, 8(1) : 1-17.
Zhang GF,Liu X,Zhang S,Pan B,Liu ML .2018 .Ciprofloxacin derivatives and their antibacterial activities. Eur. J. Med, 146 : 599-612.
0

Citations

0

Downloads

12

Views